Originally published as JCO Early Release 10.1200/JCO.2005.10.080 on March 28 2005
Journal of Clinical Oncology, Vol 23, No 19 (July 1), 2005: pp. 4275-4286
© 2005 American Society of Clinical Oncology.
Efficacy of Prophylactic Mastectomy in Women With Unilateral Breast Cancer: A Cancer Research Network Project
Lisa J. Herrinton,
William E. Barlow,
Onchee Yu,
Ann M. Geiger,
Joann G. Elmore,
Mary B. Barton,
Emily L. Harris,
Sharon Rolnick,
Roy Pardee,
Gail Husson,
Ana Macedo,
Suzanne W. Fletcher
From the Cancer Research Network, Kaiser Permanente Northern California, Oakland; Kaiser Permanente Southern California, Pasadena, CA; Group Health Cooperative; University of Washington Department of Biostatistics and School of Medicine, Seattle, WA; Harvard Pilgrim Health Care and Harvard Medical School, Boston, MA; Kaiser Permanente Northwest Center for Health Research, Portland, OR; and HealthPartners, Minneapolis, MN
Address reprint requests to Lisa J. Herrinton, PhD, Division of Research, Northern California Kaiser Permanente, 2000 Broadway Ave, Oakland, CA 94612; e-mail: lisa.herrinton{at}kp.org
PURPOSE: We investigated the efficacy of contralateral prophylactic mastectomy (CPM) in reducing contralateral breast cancer incidence and breast cancer mortality among women who have already been diagnosed with breast cancer.
METHODS: This retrospective cohort study comprised approximately 50,000 women who were diagnosed with unilateral breast cancer during 1979 to 1999. Using computerized data confirmed by chart review, we identified 1,072 women (1.9%) who had CPM. We obtained covariate information for these women and for a sample of 317 women who did not undergo CPM.
RESULTS: The median time from initial breast cancer diagnosis to the end of follow-up was 5.7 years. Contralateral breast cancer developed in 0.5% of women with CPM, metastatic disease developed in 10.5%, and subsequent breast cancer developed in 12.4%; 8.1% died from breast cancer. Contralateral breast cancer developed in 2.7% of women without CPM, and 11.7% died of breast cancer. After adjustment for initial breast cancer characteristics, treatment, and breast cancer risk factors, the hazard ratio (HR) for the occurrence of contralateral breast cancer after CPM was 0.03 (95% CI, 0.006 to 0.13). After adjustment for breast cancer characteristics and treatment, the HRs for the relationship of CPM with death from breast cancer, with death from other causes, and with all-cause mortality were 0.57 (95% CI, 0.45 to 0.72), 0.78 (95% CI, 0.57 to 1.06), and 0.60 (95% CI, 0.50 to 0.72), respectively.
CONCLUSION: CPM seems to protect against the development of contralateral breast cancer, and although women who underwent CPM had relatively low all-cause mortality, CPM also was associated with decreased breast cancer mortality.
Supported by grant No. U19 CA NCI 79689 from the National Cancer Institute, Bethesda, MD.
Authors disclosures of potential conflicts of interest are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
Related Editorial
- Contralateral Prophylactic Mastectomy: Quantifying Benefits and Weighing the Harms
Kathy J. Helzlsouer
JCO 2005 23: 4251-4253
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
D G R Evans, A D Baildam, E Anderson, A Brain, A Shenton, H F A Vasen, D Eccles, A Lucassen, G Pichert, H Hamed, et al.
Risk reducing mastectomy: outcomes in 10 European centres
J. Med. Genet.,
April 1, 2009;
46(4):
254 - 258.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Tuttle, S. Jarosek, E. B. Habermann, A. Arrington, A. Abraham, T. J. Morris, and B. A. Virnig
Increasing Rates of Contralateral Prophylactic Mastectomy Among Patients With Ductal Carcinoma In Situ
J. Clin. Oncol.,
March 20, 2009;
27(9):
1362 - 1367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Recht
Contralateral Prophylactic Mastectomy: Caveat Emptor
J. Clin. Oncol.,
March 20, 2009;
27(9):
1347 - 1349.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Mor and K. Oberle
Ethical Issues Related To BRCA Gene Testing in Orthodox Jewish Women
Nursing Ethics,
July 1, 2008;
15(4):
512 - 522.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S. van Dijk, M. S. van Roosmalen, W. Otten, and P. F.M. Stalmeier
Decision Making Regarding Prophylactic Mastectomy: Stability of Preferences and the Impact of Anticipated Feelings of Regret
J. Clin. Oncol.,
May 10, 2008;
26(14):
2358 - 2363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Briasoulis and D. H. Roukos
Contralateral Prophylactic Mastectomy: Mind the Genetics
J. Clin. Oncol.,
April 10, 2008;
26(11):
1909 - 1910.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Tuttle, E. B. Habermann, and B. A. Virnig
In Reply
J. Clin. Oncol.,
April 10, 2008;
26(11):
1910 - 1910.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Metcalfe, J. Lubinski, P. Ghadirian, H. Lynch, C. Kim-Sing, E. Friedman, W. D. Foulkes, S. Domchek, P. Ainsworth, C. Isaacs, et al.
Predictors of Contralateral Prophylactic Mastectomy in Women With a BRCA1 or BRCA2 Mutation: The Hereditary Breast Cancer Clinical Study Group
J. Clin. Oncol.,
March 1, 2008;
26(7):
1093 - 1097.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. J. Brenner, I. Shuryak, S. Russo, and R. K. Sachs
In Reply:
J. Clin. Oncol.,
February 20, 2008;
26(6):
1015 - 1016.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Tuttle, E. B. Habermann, E. H. Grund, T. J. Morris, and B. A. Virnig
Increasing Use of Contralateral Prophylactic Mastectomy for Breast Cancer Patients: A Trend Toward More Aggressive Surgical Treatment
J. Clin. Oncol.,
November 20, 2007;
25(33):
5203 - 5209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. N. Weitzel, V. I. Lagos, C. A. Cullinane, P. J. Gambol, J. O. Culver, K. R. Blazer, M. R. Palomares, K. J. Lowstuter, and D. J. MacDonald
Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer
JAMA,
June 20, 2007;
297(23):
2587 - 2595.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. D. Lehman, C. Gatsonis, C. K. Kuhl, R. E. Hendrick, E. D. Pisano, L. Hanna, S. Peacock, S. F. Smazal, D. D. Maki, T. B. Julian, et al.
MRI Evaluation of the Contralateral Breast in Women with Recently Diagnosed Breast Cancer
N. Engl. J. Med.,
March 29, 2007;
356(13):
1295 - 1303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Wallace
Reshaping Cancer Learning Through The Use Of Health Information Technology
Health Aff.,
March 1, 2007;
26(2):
w169 - w177.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. P. Tercyak, B. N. Peshkin, B. M. Brogan, T. DeMarco, M. F. Pennanen, S. C. Willey, C. M. Magnant, S. Rogers, C. Isaacs, and M. D. Schwartz
Quality of Life After Contralateral Prophylactic Mastectomy in Newly Diagnosed High-Risk Breast Cancer Patients Who Underwent BRCA1/2 Gene Testing
J. Clin. Oncol.,
January 20, 2007;
25(3):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Geiger, C. N. West, L. Nekhlyudov, L. J. Herrinton, I.-L. A. Liu, A. Altschuler, S. J. Rolnick, E. L. Harris, S. M. Greene, J. G. Elmore, et al.
Contentment With Quality of Life Among Breast Cancer Survivors With and Without Contralateral Prophylactic Mastectomy
J. Clin. Oncol.,
March 20, 2006;
24(9):
1350 - 1356.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Vogt and E. H. Wagner
Introduction
J Natl Cancer Inst Monographs,
November 1, 2005;
2005(35):
1 - 2.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Nekhlyudov, M. Bower, L. J. Herrinton, A. Altschuler, S. M. Greene, S. Rolnick, J. G. Elmore, E. L. Harris, A. Liu, K. M. Emmons, et al.
Women's Decision-Making Roles Regarding Contralateral Prophylactic Mastectomy
J Natl Cancer Inst Monographs,
November 1, 2005;
2005(35):
55 - 60.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. N. West, A. M. Geiger, S. M. Greene, E. L. Harris, I.-L. A. Liu, M. B. Barton, J. G. Elmore, S. Rolnick, L. Nekhlyudov, A. Altschuler, et al.
Race and Ethnicity: Comparing Medical Records to Self-Reports
J Natl Cancer Inst Monographs,
November 1, 2005;
2005(35):
72 - 74.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. J. Helzlsouer
Contralateral Prophylactic Mastectomy: Quantifying Benefits and Weighing the Harms
J. Clin. Oncol.,
July 1, 2005;
23(19):
4251 - 4253.
[Full Text]
[PDF]
|
 |
|
|